IP Library Patent Application 13089704
Patent Application
App. No. 13/089,704

Antifungal Treatment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/089,704
Abstract

A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is compound 13 or 33 and is combined with an azole compound, such as fluconazole.

Claims (45)

1 . A method for treating fungal infection, comprising:

(a) identifying a plant or animal having a fungal infection; and

(b) administering an effective amount of an anti-fungal compound to the plant or animal, wherein the amount is effective to reduce the fungal infection and wherein the compound comprises formula I or formula IV.

2 . The method of claim 1 wherein the compound comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

3 . The method of claim 1 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

4 . The method of claim 1 wherein the histidine kinase-dependent anti-fungal compound comprises at least one of:

or a salt, prodrug, solvate or hydrate thereof.

5 . The method of claim 1 additionally comprising administering an amount of an azole compound effective to reduce fungal infection.

6 . The method of claim 5 wherein the azole is fluconazole.

7 . The method of claim 1 , wherein the compound is a histidine kinase-dependent antifungal compound.

8 . The method of claim 7 , wherein the histidine kinase is Drk1.

9 . A method for preventing a fungal infection, comprising:

administering an effective amount of a composition of formula I or IV to a plant or animal,

wherein the amount is effective to prevent a fungal infection.

10 . The method of claim 9 wherein the compound comprises a compound of formula (I):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

11 . The method of claim 9 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

12 . The method of claim 9 wherein the compound comprises at least one of:

or a salt, prodrug, solvate or hydrate thereof.

13 . The method of claim 9 additionally comprising administering an amount of an azole compound effective to reduce fungal infection.

14 . The method of claim 9 wherein the azole is fluconazole.

15 . A pharmaceutical dosage form comprising an effective amount of the compound of claim 1 and a pharmaceutically suitable carrier system.

16 . The dosage of claim 15 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

17 . The pharmaceutical dosage form of claim 15 , wherein the dosage form comprises an oral, injection, infusion, inhalation, transdermal, or implant dosage form.

18 . The dosage of claim 15 wherein the compound comprises a compound of formula (IV):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

19 . The dosage of claim 16 additionally comprising an azole compound.

20 . The dosage of claim 18 additionally comprising an azole compound.

21 . An agricultural preparation comprising the compound of claim 1 .

22 . The dosage of claim 21 wherein the compound comprises a compound of formula (IV):

wherein is an alkane, alkene, or alkyne, and R 5 is selected from the group consisting of formulas (V), (VI), (VII), and (VIII):

or a salt, prodrug, solvate or hydrate thereof.

23 . The dosage of claim 21 wherein the compound comprises a compound of formula (IV):

wherein R 1 is >S or oxidized >S, R 2 and R 3 are independently selected from formulas (II) and (III):

and R 4 is >S or oxidized >S, or a salt, prodrug, solvate or hydrate thereof.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 22, 2019
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049638/0237 →
CONFIRMATORY LICENSE Recorded Jul 19, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 046592/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: TEBBETS, BRAD; KLEIN, BRUCE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 026516/0500 →